Roth Report, page-36

I refrain from being an optimist but I've been naively looking at some information about Amgen and its acquisition of BioVex. It took close to 1.5 years - after BioVex had published its Phase II results for T-Vec in the Journal of Clinical Oncology - for Amgen to go ahead and acquire BioVex. I don't recall Viralytics publishing a scientific paper for its Phase II results. However, we're at almost the one-year mark since the final Phase II results were presented at the ASCO Annual Meeting 2015. Just for comparison.

I'm not so curious about the efficacy of CAVATAK (as it continues to show promising results) but more so about the commercial perception of CAVATAK. The numbers 'look' good but I'm curious about what other factors these heavy hitters are taking into account when looking at CAVATAK. At least with Amgen, they were ready to scoop up BioVex only after its Phase II results were released. Was this indicative of management effectiveness and/or clinical efficacy promise? Do they see CAVATAK as a superior/inferior substitute? I find it confusing (as I'm new to this) and interesting at the same time in seeing how the story of Viralytics unravels. Definitely looking forward to the results in June at ASCO.